INTRODUCTION
============

Histone acetylation is the most thoroughly studied and appreciated post-translational modifi cation mechanism [@B021]. Generally, transcriptionally activeeuchromatin domains tend to be relatively hyperacetylated whereas transcriptionally repressed heterochromatin domains arehypoacetylated [@B019]; [@B022]. The acetylation status of histones is regulated by the opposing action of two classes of enzymes, histone acetyl transferases (HATs) and histone deacetylases (HDACs) [@B033]; [@B025]. Acetylation of the histone tails enhance the accessibility of transcription factors, transcriptional regulatory complexes, and RNA polymerases to promoter regions of DNA [@B029]; [@B030]; [@B032]; [@B031]. This explains the role of HATs as transcriptional coactivators, and DNA binding proteins including PCAF (p300/cyclic AMP-response-element binding protein-associated factor) and members of the p300/CBP family of transcriptional coactivators can recruit them to their site of action [@B028]; [@B032]. However, theacetyltransferase activity of HATs extends beyonds histones; various nuclear proteins, in particular transcription factors such as p53, GATA-1, E2F, estrogen receptor, and various cellcycle regulatory proteins with variable functional consequences [@B025]; [@B032]; [@B027]. HDACs counteract the activity of HATs and catalyse the removal of acetyl groups from lysine residues in histone N-terminus, leading to chromatin condensation and transcrip-tional repression [@B010]; [@B011]; [@B020].

This condensed chromatin structure inhibits transcription, presumably, because transcription factors, transcriptional regulatory complexes, and RNA polymerase do not have access to the DNA. In addition, HDACs are part of multiprotein transcriptional repressor complex or interact with DNA binding proteins. In addition to regulating the acetyla-tion state of histones, histone deacetylase (HDAC) can bind to, deacetylate and regulate the activity of a number of other proteins, including transcription factors such as p53, E2F transcription factor 1 (E2F1), STAT1, STAT3, and nuclear factor-κB (NF-κB) and proteins with diverse biological functions such as α-tubulin, Ku70, and heat-shock protein 90 (Hsp90) [@B003]. While histones still represent primary targets for the physiological function of HDACs, the antitumor effects of HDAC inhibitors might also be attributed to transcription-independent mechanisms by modulating the acetylation status of a series of non-histone targets. HDAC inhibitors can affect tumor cell growth andsurvival through multiple biological effects. HDAC inhibitors induce cell cycle arrest and apoptosis, and have anti-angiogenic and immunomodulatory effects by modulating the acetylation of a series of non-histone proteins. HDAC inhibitors have been found to induce cell growth arrest, differentiation, and/or apoptosis, and exhibit potent antimetastatic, antiangiogenic, and immuno-modulatory properties in a variety of transformed cells *in vitro* and *in vivo* that can contribute to the inhibition of tumour development andprogression [@B027]; [@B023]; [@B024]. The treatment of normal and tumor cells with HDAC in-hibitors causes a similar accumulation of acetylated histones H4, H3, H2A, H2B [@B027]; [@B034]; [@B035]. Nevertheless, tumor cells appear to be much more sensitive to growth arrest, differentiation, and apoptotic effects of these agents than normal cells [@B028]; [@B005], [@B006], [@B007]; [@B026]; [@B023].

In this study, we tried to evaluate the anti-tumor effects of various HDAC inhibitors on MDA-MB-231 human breast cancer. Moreover, the underlying chemotherapeutic mechanisms of them were explored also. To examine the anti-tumor effect of HDAC inhibitors, we examined the effect of HDAC inhibitors on the cell proliferation, cell cycle distribution, and apoptosis in MDA-MB-231 human breast cancer cells. To find out the mechanism of anti-tumor activity of HDAC inhibitors, we examined the effect of IN-2001 on the expression of cell cycle regulatory protein and apoptosis-related proteins.

MATERIALS AND METHODS
=====================

Chemicals
---------

HDAC inhibitors, such as Trichostatin A, IN2001, SAHA, and LAQ were gnerously provided from Dr. D. K. Kim (EwhaWomans University, Seoul, South Korea). HC toxin was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Sodium pyrubate, penicillin-streptomycin, fetal bovine serum (FBS), trypsin-EDTA, minimum essential medium (MEM), and RPMI were acquired from GibcoBRL (Rockvulle, MD, USA). Antibodies were from Santa Crutz Biotechnology Inc. (Santa Crutz, CA, USA).

Cell lines and cell culture conditions
--------------------------------------

MDA-MB-231 cells were obtained from Korean Cell Line Bank (KCLB, Seoul, South Korea). MDA-MB-231 cells were maintained in RPMI1640 medium, supplemented with fetal bovine serum and penicillin-streptomycin. Cells were routinely maintained at 37℃ and in 5% CO~2~.

Cell proliferation assay
------------------------

Cells were plated in 96 well plates and were treated with chemicals. Cells were treated with cold 10% trichloroacetic acid (TCA) and TCA-fixed cells were stained for 30 min with 0.4% (w/v) sulforhodamineB (SRB) dissolved in 1% acetic acid. Bound dye was solubilized with 10 mM Tris base (pH 10.5) and optical dencity was read using ELISA reader (Bio-Rad, Hercules, CA, USA) at 570 nm.

Flow Activated Cell Sorter (FACS) Analysis
------------------------------------------

Chemicals treated cells were detached using trypsin-EDTA and fixed with 70% ethanol. After centrifugation, the cells were treated with RNase A (10 μg/ml) and stained with propidium iodide (2 μg/ml). The DNA content per cell was evaluated in a FACScalibur (Becton Dickinson, San Diego, CA, USA).

RT-PCR analysis
---------------

Total RNA was extracted using Trizol reagnt (Invitrogen Co., Carlsbad, CA, USA) from cells were exposed to chemicals for 24 hr. Reverse transcription was carried out on total RNA in a mixture containing random prime, dNTPs, DTT, RT buffer (5X), M-MLV reverse transcriptase, RNase in at 37℃ for 1 hr. cDNA was stored at -20℃ or cDNA was subjected to PCR amplification with special primer (GAPDH; 5'AC ATCgCTCAgACACCATgg3'; 5'gTAgTTgAggTCAAT g AA -ggg3': p21; 5'gAACTTCgACTTTgTCACCgAg3'; 5'Cg TTTTCgACCCTgAg AgTCTC3': Cyclin D1; 5'AgCCATggAACAC-CAgCTC3'; 5'gCACCTCCAgCATCCAggT3': Cyclin D2; 5'T A CTTCAAgTgCgTgCAgAAggAC3'; 5' TCCCACACTTCC-AgTTgCgATCAT3') in reaction containing dNTP and Taqpolymerase. DNA was denatured at 95℃ extended at 72℃ and PCR products were analyzed on 2% agarose gls.

Western blot analysis
---------------------

After the incubation with chemicals for 24 hr, cells were homogenized in a lysis buffer (Pro-prep protein extraction solution, INtRON; 20 mM Tris, 160 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.25% sodium deoxycholate, 1 mM PMSF, 1 mM NaF, 1 mM dithiothreitol (DTT), 1 mM sodium orthovanadate, pepstatin, leupeptin, and aprotinin) on ice and cell lysates were centrifuged at 14,000 g for 5 min at 4°C, divided into aliquots and stored at -80°C. Protein was separated by electrophoresis on 10-15% SDS-acrylamide gels and then electrophoretically transferred to polyvinylidenedifluoride (PVDF) transfer membrane (Hybond-P; Amersham). Membranes were blocked with 3% dry milk in PBST

![Structures of HDAC inhibitors.](ooomb4-20-313-g001){#F001}

(PBS with 0.1% Tween) overnight at 4°C and incubated with specific first antibodies and second antibodies conjugated to horse radish peroxidase. Membranes were washed and air dried for ECL detection (ECL Plus; Amersham).

RESULTS
=======

IN-2001 causes dose-dependent growth inhibition
-----------------------------------------------

In recent years, an increasing number of structurally diverse HDAC inhibitors have been identified as an exciting new class of potential anti-cancer agents. In this study, we evaluated the anti-tumor effects of various kinds of HDAC inhibitors ([Fig. 1](#F001){ref-type="fig"}) in the human breast cancer cells in an attempt to find out better therapeutic agents for breast cancer treatment. To determine the antiproliferative effect of IN-2001 on the human breast cancer MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or various concentrations (0.001-10 μM) of IN-2001 for 72 hr and then the number of cells was determined based on the SRB assay.

As shown in [Fig. 2](#F002){ref-type="fig"}, IN-2001showed anti-proliferative effect in a dose-dependent manner. The IC~50~ values of HDAC inhibitors in each cell lines were shown in [Table 1](#T001){ref-type="table"}. These data indicated that the anti-proliferative effects of HDAC inhibitors were cell type specific and ER positive breast cancer cells seemed to be more susceptible to HDAC inhibitors than ER negative breast cancer cells.

IN-2001 time-dependent growth inhibition
----------------------------------------

In the next experiment, we carried out time-course experiment with 1 μM IN-2001. As shown in [Fig. 3](#F003){ref-type="fig"}, IN-2001 decreased the proliferation of MDA-MB-231 human breast cancer cells in a time-dependent manner. MDA-MB-231 cells

![Dose-dependent growth inhibition by IN-2001. MDAMB-231 human breast cancer cells were treated with vehicle (0.1%DMSO) or indicated concentrations (0.001-10 μM) of IN-2001 for 72 hr. The number of cells was determined by SRB assay and cell proliferation was expressed as percent of control. Data presentmean ± S.D. (N=4).](ooomb4-20-313-g002){#F002}

###### 

50% inhibitory concentration (IC~50~) of HDAC inhibitor

  -------- -------------
           IC~50~ (μm)
           
  IN2001   0.585
  SAHA     0.923
  -------- -------------

showed significant growth inhibition when cells were exposed to for more than 24 hr. In MDA-MB-231 cells, cell growth was decreased by 10-15% over control with IN-2001 treatment for 24.

IN-2001 induces cell cycle arrest
---------------------------------

To investigate whether the gowth inhibitory effect of IN-2001 is related to cell cycle alteration, we analyzed the cell cycle distribution of IN-2001-treated breast cancer cells. ER negative MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM IN-2001 for various time periods (12, 24, or 48 hr) and then analyzed cell cycle distribution by flow cytometric analysis after PI staining their DNA. Representative histograms and quantitative analysis data are shown in [Fig. 4](#F004){ref-type="fig"} and [Table 2](#T002){ref-type="table"}, respectively. As shown in [Fig. 4](#F004){ref-type="fig"}, IN-2001 showed G~2~/M arrest with decrease of G~0~/G~1~ phase or S phase in MDA-MB-231 cells. When cells were treated with IN-2001 for 12 hr, MDA-MB-231 cells yielded 42.7% of cells in G~2~/M phase,

![Time-dependent growth inhibition by IN-2001. Human breast cancer MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM IN-2001 for various exposure time (0-72 hr). The number of cells was determined by SRB assay and cell proliferation was expressed as percent of control. Data present mean ± S.D. (N=4).](ooomb4-20-313-g003){#F003}

![Effect of IN-2001 on cell cycle distribution. MDA-MB-231.Human breast cancer cells were treated with vehicle (0.1% DMSO)or 1 μM IN-2001 for the indicated time periods. Cells were harvested, fixed, and stained with PI. Then 20,000 stained cells were subjected to flow cytometry analysis to determine the distribution of cells.](ooomb4-20-313-g004){#F004}

###### 

Cell cycle distriburtion by IN-2001

  ------------ ----------------- ---------------------------- ---------------- ---------------- ------------------------
  Times (hr)   HDAC inhibitors   Distributions of cells (%)                                     
                                                                                                
                                 Sub-G~1~                     G~0~/G~1~        S                G~2~/M
                                                                                                
  12           Ctrl              1.706 ± 0.212                53.832 ± 0.655   11.487 ± 0.291   34.314 ± 0.731
               IN2001            2.376 ± 0.281                49.477 ± 0.883   7.878 ± 0.267    **42.667 ± 1.089^\*^**
               SAHA              2.678 ± 0.352                54.997 ± 1.681   10.299 ± 0.436   33.762 ± 1.369
  24           Ctrl              2.067 ± 0.151                59.915 ± 0.916   12.870 ± 0.211   26.936 ± 0.714
               IN2001            2.845 ± 0.237                52.017 ± 1.137   5.565 ± 0.284    **42.418 ± 0.906^\*^**
               SAHA              3.078 ± 0.027                60.993 ± 0.481   12.502 ± 0.702   26.497 ± 0.555
  48           Ctrl              2.583 ± 0.155                61.213 ± 1.107   10.910 ± 0.112   27.275 ± 1.182
               IN2001            7.595 ± 0.802                49.338 ± 0.645   11.542 ± 0.480   **39.458 ± 0.796^\*^**
               SAHA              3.474 ± 0.712                62.667 ± 1.675   10.879 ± 0.590   26.103 ± 1.341
  ------------ ----------------- ---------------------------- ---------------- ---------------- ------------------------

\*Bold lettering indicates significant difference from control group (p\<0.05).

![Effect of HDAC inhibitor on the expression of cdk inhibitor. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr. Total RNA was isolated and then subjected to RT-PCR using specific primers. GAPDH served as loading control. For quantification the band intensity of p21WAF1 was normalized to that of GAPDH and data was expressed as fold induction compared to control group.](ooomb4-20-313-g005){#F005}

whereas untreated control cells showed 34.3% of cells in G~2~/M phase. With 24 hr treatment IN-2001 accumulated 42.4% of cells in G~2~/M phase, whereas untreated control cells showed 26.9% of cells in G~2~/M phase. When cells were treated with IN-2001 for 48 hr showed 39.5% of cells in G~2~/M phase, whereas untreated control cells showed 27.3% of cells in G~2~/M phase. SAHA did not affect cell cycle distribution of MDA-MB-231 cells.

IN-2001 increases p21^WAF1^ and p27^KIP1^ expression
----------------------------------------------------

In the previous study, we found that HDAC inhibitors induced cell cycle arrest. In relation to cell cycle arrest, we examined the effects of HDAC inhibitorson the cell cycle regulatory proteins, such as cyclins and cyclin dependent kinase (cdk) inhibitors. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM IN-2001 for 24 hr. And then the expression of cdk inhibitors, such as p21^WAF1^ and p27^KIP1^ was examined by RT-PCR and western blot analysis. As shown in [Fig. 5](#F005){ref-type="fig"} in MDA-MB-231 cells, IN2001, and SAHA slightly increased p21WAF1 mRNA level. In contrast, p21WAF1 protein level was significantly up-regulated by all kinds of IN-2001 ([Fig. 6](#F006){ref-type="fig"}). IN-2001, and SAHA treatment showed 1.9-fold, and 1.4-fold in-crease in p21^WAF1^ protein level, respectively. In addition, p27^KIP1^ protein level was also increased to 2.6-fold, and 1.5-fold with IN2001, and SAHA, respectively.

These results suggested that the HDAC inhibitor-induced up-regulation of cdk inhibitor may lead to cell cycle arrest, ultimately resulting in growth inhibition.

IN-2001 decreases cyclin D1 expression and increases cyclin D2 expression
-------------------------------------------------------------------------

As well as cdk inhibitors, one of the important cell cycle regulatoryproteins is cyclin. In this study, we examined the effect of IN-2001 on the expressions of D-type cyclin (cyclin D1 and cyclin D2). MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM IN-2001 for 24 hr and then examined for the expression of cyclin D1 and cyclin D2 by RT-PCR analysis. In MDA-MB-231 cells, TSA, HC toxin, and LAQ significantly down-regulated cyclin D1 mRNA level but did not change cyclin D2 mRNA level. Cyclin D2 mRNA level was up-regulated by IN-2001 and SAHA to 1.6-fold and 1.8-fold, respectively ([Fig. 7](#F007){ref-type="fig"}).

HDAC inhibitor decreases thymidylate synthase expression
--------------------------------------------------------

Thymidylate synthase (TS) is an essential enzyme for DNA replication and repair because it provides the sole intracellular source of dTMP. Thus, it has been a major target of chemotherapeutic agents, such as fluoropyrimidines (i.e. 5-FU) and antifolates (i.e. TDX, ZD931, and MTA). Therefore, we examined the effect of HDAC inhibitor on the TS gene expression. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr and then TS mRNA level was determined using RT-PCR technique. As shown in [Fig. 8](#F008){ref-type="fig"}, TSA, HC toxin, IN-2001, and LAQ treatment decreased TS mRNA level to 24%, 22%, 80%, and 33% of control level, respectively in MDA-MB-231 cells. But SAHA did not show significant

![Effect of IN-2001 on the expression of cdk inhibitor. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM IN-2001 for 24 hr.Protein extracts were prepared and 50 μg of protein extracts were separated by 12% SDS-PAGE. Blots were probed with the corresponding antibodies. Actin served as the loading control. For quantification, the band intensity of p21^WAF1^ and p27^KIP1^ was normalized to that of Actin and data was expressed as fold induction compared to control group.](ooomb4-20-313-g006){#F006}

changes in TS expression, instead slightly increased TS expression.

HDAC inhibitor induces dose-dependent apoptosis
-----------------------------------------------

To determine whether anti-proliferative effect of HDAC inhibitor is related with induction of apoptosis, we examined the effect of HDAC inhibitor on the apoptosis. Moreover, we tried to elucidate the underlying mechanism of apoptosis induced by HDAC inhibitors. MDA-MB-231 cells treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for various time period (12 hr, 24 hr, or 48 hr). And then cell were stained with fluorescent PI dye and then subjected to FACS analysis to measure the sub-G~1~ populations, which represent apoptotic cells with less than 2N DNA content. In MDA-MB-231 cells, 1μM HDAC inhibitors did not show significant sub-G~1~ peak when cells were exposed for 12 hr. As the exposure time increased, apoptotic cells were detected. TSA, HC toxin, and LAQ treatement for 24 hr showed 7%, 7.6%, and 8% of sub-G~1~peak, respectively, whereas untreated control cells showed 2.1% of

![Effect of IN-2001 on the cyclin D expression. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM IN-2001 for 24 hr. Total RNA was isolated and then subjected to RT-PCR using specific primers. GAPDH served as the loading control. For quantifi cation the band intensity of cyclin D was normalized to that of GAPDH and data was expressed as fold induction compared to control group (p\<0.05). ^\*^Significantly different from control.](ooomb4-20-313-g007){#F007}

sub-G~1~ peak. When cells were exposed to HDAC inhibitors for 48 hr, HDAC inhibitors except SAHA increased apoptotic peak ranging from 7.6% to12.9% compared to the control value of 2.6%. However, 1 μM SAHA did not show apparent apoptotic sub-G~1~ peak ([Fig. 9](#F009){ref-type="fig"}).

DISCUSSION
==========

In cancer, some genes are transcriptionally silenced by the inappropriated recruitment of HDACs, *e.g*., tumor suppressor genes [@B018]. Known repressors are multiproteins that contain DNA binding proteins (*e.g*., NcoR, SMRT, MEF, MeCP2, and sin3A) that commonly use HDACs to repress transcription and block the function of the tumor suppressor gene. The archetypical gene silenced in this manner in human cancer is the cyclin-dependent kinase inhibitor p21^WAF1^. Epigenetic reactivation of p21^WAF1^ by HDAC inhibitors has been reported in cancer cell lines [@B001], and the restoration of p21^WAF1^ gene expression by HDAC inhibitors

![Effect of HDAC inhibitor on the thymidylate synthase expression. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr. Total RNA was isolated and then subjected to RT-PCR using specific primers for thymidylate synthase. GAPDH served as the loading control. For quantification, the band intensity of TS was normalized to that of GAPDH and data was expressed as fold induction compared to control group. ^\*^Significantly different from control (p\<0.05).](ooomb4-20-313-g008){#F008}

![Quantitative analysis of HDAC inhibitor-induced apoptosis. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 12, 24 or 48 hr. Cells were harvested, fixed, and stained with PI. Then 20,000 stained cells were subjected to flow cytometry analysis. Quantitative analysis of apoptosis was done using ModiFit program. Data present mean ± S.D. (N=4). ^\*^Significantly different from control at each time point (p\<0.05).](ooomb4-20-313-g009){#F009}

is associated with enrichment of hyperacetylated histones at the p21^WAF1^ promoter [@B022]. Demethylatingagents such as 5-aza-2\'-deoxycytidine are particularly interesting owing to the interaction of DNA methylation with histone deacetylation in gene silencing of tumor suppressor genes. Combinations of 5-aza-2\'-deoxycytidine with HDAC inhibitors, TSA or depsipeptide, were shown to reactivate silenced tumor suppressor genes including MLH1, TIMP3, CDKN2B, CDKN2A, ARHI, gelsolin, and maspin, synergstically increasing the level of tumor cell apoptosis [@B013]. [@B027] have proposed a mechanism of action of HDAC inhibitors that induce tumor growth arrest, differentiation, and/or apoptosis. With inhibition of HDAC, histones are acetylated, and the DNA that is tightly wrapped around a highly charged deacetylated histone core relaxes. Inhibition of HDAC activity generates acetylation of histones in nucleosomes, resulting in a more open chromatin structure. The relaxed chromatin structure allows expression of specific set of programmed genes, which, in turn, leads to cell growth arrest, differentiation, and/or apoptotic cell death and, as a consequence, inhibition of tumor growth. HDAC inhibitors may achieve their antitumor effects through reactivation of dormant tumor suppressor genes [@B014]; [@B015]; [@B017]; [@B016]; [@B036]. In addition to stand alone-therapeutics for chemotherapy, HDAC inhibitors seem to be suitable for combination therapy as "sensitizer drugs", enhancing the antitumor effects of specific chemotherapeutics. In fact, a proportion of the clinical trials using HDAC inhibitors involve a combination of an established antitumor compound together with a HDAC inhibitor [@B009]; [@B008]; [@B012]; [@B036]. The drug combinations may have 2 advantages: first, the dose of each substance necessary for cell growth inhibition or apoptosis is usually much lower than if used separately, reducing side effects and toxicity, and second, resistance to certain chemicals can be overcome in some cases by combining drugs. For instance, cell death after treatment with etoposide, comptothecin, and other substances that cross-link DNA and Topo II enzymes increases if the cell lines are pretreated with either TSA and SAHA, probably because the chromatin changes caused by the hydroxamic acids facilitate cross-linker access to the target. Combinations of nuclear receptor ligands, such as all *trans* retinoic acid (ATRA), or vitamin D analaogs, such as 1,25-dihydroxyvi-tamin D, with HDAC inhibitors have been shown to increase differentiation and apoptosis in cancer cells and also inhibit tumor growth in vivo [@B002]; [@B004]; [@B013].
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